Shares of Exelixis Inc. (EXEL) rose 1.9% to $25.70 in premarket trading on Monday, July 10, after the South San Francisco, Calif.-based firm and Bristol-Myers Squibb Co. (BMY) announced they have started a Phase 3 study of  Opdivo (nivolumab) in tandem with Cabometyx (cabozantinib) tablets or Opdivo and Yervoy (ipilimumab) in combination with Cabometyx versus sunitinib in patients with previously untreated, advanced or metastatic renal cell carcinoma.

Other biotech movers include Omeros Corp. (OME) R, up 7.9% to $20.61 and Inovio Pharmaceuticals Inc. (INO) , up 3.1% to $8.12.

Worried about how to finance your golden years? Register here to watch a webinar in which TheStreet's Jim Cramer talks with Ken Fisher, founder of Fisher Investments, about the market trends shaping retirement planning today.

If you liked this article you might like

Biotech Movers: Disappointment for Bristol-Myers Kidney Combo Boosts Exelixis

Carnival, Tableau Software, Groupon, Newell Brands: 'Mad Money' Lightning Round

Market Stands at a Make-Or-Break Level: Cramer's 'Mad Money' Recap (Monday 7/17/17)

Exelixis Has an Enviable Chart Pattern